Livmoniplimab (ABBV-151; ARGX-115) is a humanised monoclonal antibody targeting LRRC32 (GARP)/TGFβ1, which blocks TGFβ1 release mediated by LRRC32, for the treatment of locally advanced or metastatic solid tumours.

Method:
Seven-week-old female B-hGARP mice were subcutaneously inoculated with MC38 mouse colon cancer cells to establish tumor models. Livmoniplimab was administered at a dose of 250 μg via intraperitoneal injection three times a week for 3 weeks to evaluate its antitumor efficacy.

Result:
Livmoniplimab treatment Resulted in a 34.3% inhibition of tumor growth. [2]